IDH2 and acute myeloid leukemia: The combination of frontline enasidenib + azacitidine has demonstrated a superior overall response rate compared to azacitidine alone in patients with IDH2-mutated AML ineligible for intensive chemotherapy, but enasidenib is not currently approved in the frontline setting (9).